Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.

Date publication

septembre 2015

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe

Tous les auteurs :
Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26208462

Résumé

There is an urgent need for qualified predictive biomarkers of sensitivity for the treatments used in patients with castration-resistant prostate cancer (CRPC). We attempted to identify ready-to-use clinical predictors of improved outcome in metastatic CRPC (mCRPC) patients treated with next generation androgen receptor (AR) axis targeted drugs.

Mots clés

Adult, Aged, Androgen Antagonists, therapeutic use, Antineoplastic Agents, Hormonal, therapeutic use, Disease-Free Survival, France, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Phenylthiohydantoin, analogs & derivatives, Proportional Hazards Models, Prostatic Neoplasms, Castration-Resistant, drug therapy, Receptors, Androgen, drug effects, Retrospective Studies, Signal Transduction, drug effects, Time Factors, Treatment Outcome

Référence

Eur. J. Cancer. 2015 Sep;51(14):1946-52